Literature DB >> 12605397

Reduced-intensity bone marrow transplantation from an alternative unrelated donor for myelodysplastic syndrome of first-donor origin.

Yukiko Komeno1, Yoshinobu Kanda, Koji Kandabashi, Masahito Kawazu, Susumu Goyama, Masataka Takeshita, Yasuhito Nannya, Miyuki Niino, Tetsuya Nakamoto, Mineo Kurokawa, Shiho Tsujino, Seishi Ogawa, Katsunori Aoki, Shigeru Chiba, Toru Motokura, Hisamaru Hirai.   

Abstract

A male patient had a relapse of myelodysplastic syndrome (MDS) 2 years after BMT from a female matched unrelated donor. Conventional cytogenetics, FISH, and short-tandem repeat chimerism analysis proved a relapse of donor origin. He underwent reduced-intensity BMT after a conditioning with fludarabine and busulfan, since he had impaired renal, liver, and pulmonary functions. Chimerism analysis on day 28 after the second BMT showed mixed chimerism of the first and the second donors, which later turned to full second-donor chimerism on day 60. He developed grade II acute GVHD of the skin and cytomegalovirus reactivation, but both were improved with methylprednisolone and ganciclovir, respectively. He remains in complete remission 6 months after the second BMT. Reduced-intensity second BMT from an alternative donor appeared to be a tolerable treatment option for donor-derived leukemia/MDS after the first conventional transplantation. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12605397     DOI: 10.1002/ajh.10286

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  5 in total

1.  Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges.

Authors:  Nirali N Shah; Ulrike Bacher; Terry Fry; Katherine R Calvo; Maryalice Stetler-Stevenson; Diane C Arthur; Roger Kurlander; Kristin Baird; Barbara Wise; Sergio Giralt; Michael Bishop; Nancy M Hardy; Alan S Wayne
Journal:  Am J Hematol       Date:  2012-04-04       Impact factor: 10.047

Review 2.  Donor cell-derived leukemia after cord blood transplantation and a review of the literature: differences between cord blood and BM as the transplant source.

Authors:  H Shiozaki; K Yoshinaga; T Kondo; Y Imai; M Shiseki; N Mori; M Teramura; T Motoji
Journal:  Bone Marrow Transplant       Date:  2013-09-09       Impact factor: 5.483

Review 3.  Genetics of donor cell leukemia in acute myelogenous leukemia and myelodysplastic syndrome.

Authors:  Lacey Williams; Kimberley Doucette; Judith E Karp; Catherine Lai
Journal:  Bone Marrow Transplant       Date:  2021-03-08       Impact factor: 5.483

4.  Lessons Learned from Donor Cell-Derived Myeloid Neoplasms: Report of Three Cases and Review of the Literature.

Authors:  Komal Galani Deshmukh; Katalin Kelemen
Journal:  Life (Basel)       Date:  2022-04-08

5.  Donor cell myeloid sarcoma.

Authors:  Mark A Walshauser; Aileen Go; Payal Sojitra; Girish Venkataraman; Patrick Stiff
Journal:  Case Rep Hematol       Date:  2014-04-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.